dihexa drug dihexa (PNB-0408) | c-Met/HGFR Activator Dihexa | 1401708-83-5 | BGC70883

For telehealth companies, it might mark the beginning of a peptide gold rush

Early-phase human trials are small, well-controlled studies centered on safety, reproductive hormones, and surrogate markers such as ovarian reserve tests and sperm parameters ahead of any efficacy trials

Think of it this way: peptides work from the inside out, signaling your cells to repair tissue and reduce inflammation

The peptide's natural origin in gastric secretions suggests inherent biocompatibility with human physiology

By blocking NF-B, KPV reduces the production of pro-inflammatory cytokines (IL-1, TNF-, IL-6) and inflammatory mediators (PGE2, NO)

These effects promote angiogenesis, fibroblast activity, and neuromuscular stabilization, particularly in poorly vascularized tissues such as tendons and myotendinous junctions